1 mg tirzepatide FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly TrimRX | Tirzepatide: Dual Action

Observational data suggest that both drug classes are independently associated with lower dementia risk [14, 27]

Common Side Effects Nausea Diarrhea Vomiting Constipation Stomach pain Decreased appetite Headache Serious Side Effects (Less Common) Pancreatitis Gallbladder issues Kidney injury associated with dehydration from nausea or vomiting Severe allergic reactions Vision changes in type 2 diabetes patients Increased heart rate A special caution: Animal studies link oral semaglutide to a risk of thyroid C-cell tumors, leading to a boxed warning

Other Ingredients: The lotion contains various plant extracts that contribute to its benefits.

Integrating Biomedical and Sociocultural Perspectives Ultimately, understanding off-label GLP-1 RA use requires integrating biomedical insights with sociological and cultural analysis